Charles River Reports $983 Million Q3 Revenue, Raises 2026 Guidance
Charles River reported Q3 2026 revenue of $982.7M, down 2.2% YoY, with organic growth of 4.7%. Adjusted EPS rose 27.2% to $3.09. The company raised 2026 guidance, expecting 1.5% organic revenue growth and non-GAAP EPS of $11.35-$11.55. Growth was driven by Discovery and Safety Assessment and Manufacturing.
How this was made
The 30-second read
Why it matters
The raised guidance and strong margin expansion are likely to attract buying interest, especially from investors focused on biotech services.
Market read
Earnings beat and guidance raise make CRL a near‑term trade idea; sector peers may also benefit.
What to watch
Tax‑reserve reversal inflates earnings; underlying operating performance may be less robust.
Background
Charles River Laboratories International, Inc. (CRL) filed an 8‑K reporting its Q3 2026 results and updated guidance.
Ticker impact
Charles River reported Q3 2026 revenue of $982.7M and raised its 2026 revenue and non‑GAAP EPS guidance.
likely upward pressure as investors price in higher revenue growth and EPS expectations
The company increased its organic revenue outlook and EPS range, which typically supports a bullish reaction.
Market effects
Positive signal for the life‑science services sector, potentially lifting peers.
U.S. biotech and contract research markets may see modest gains.
Limited to investors tracking contract research organizations.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyCharles River Laboratories International, Inc.
Provider of preclinical and clinical laboratory services.
